AbbVie announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia, and in patients with relapsed/refractory non-Hodgkin's lymphoma. High-risk CLL patients are those with deletions of chromosome 17p or whose disease is refractory to fludarabine therapy. This Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199/GDC-0199 in patients with relapsed/refractory CLL and NHL. Secondary objectives included preliminary efficacy, including objective response rate, duration of response, time to progression, progression-free survival and overall survival.
- Health Care Industry
- chronic lymphocytic leukemia